Lung Cancer
Volume 62, Issue 1 , Pages 99-104 , October 2008

XRCC1 polymorphisms and severe toxicity in lung cancer patients treated with cisplatin-based chemotherapy in Chinese population

  • Zhonghua Wang

      Affiliations

    • Department of Medical Oncology, Cancer Hospital of Fudan University, Shanghai Medical College, No. 270 Dongan Road, Shanghai 200032, PR China
    • Corresponding Author InformationCorresponding author. Tel.: +86 21 64036901; fax: +86 21 64430160.
    • These authors contributed equally to this work.
    • ,
  • Binghe Xu

      Affiliations

    • Department of Medical Oncology, Cancer Institute & Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, PR China
    • These authors contributed equally to this work.
    • ,
  • Dongxin Lin

      Affiliations

    • Department of Etiology and Carcinogenesis, Cancer Institute & Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, PR China
    • ,
  • Wen Tan

      Affiliations

    • Department of Etiology and Carcinogenesis, Cancer Institute & Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, PR China
    • ,
  • Shiangjiin Leaw

      Affiliations

    • Department of Medical Oncology, Cancer Hospital of Fudan University, Shanghai Medical College, No. 270 Dongan Road, Shanghai 200032, PR China
    • ,
  • Xiaonan Hong

      Affiliations

    • Department of Medical Oncology, Cancer Hospital of Fudan University, Shanghai Medical College, No. 270 Dongan Road, Shanghai 200032, PR China
    • ,
  • Xichun Hu

      Affiliations

    • Department of Medical Oncology, Cancer Hospital of Fudan University, Shanghai Medical College, No. 270 Dongan Road, Shanghai 200032, PR China

Received 1 January 2008 ,Revised 18 February 2008 ,Accepted 24 February 2008.

References 

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108
  2. Mountain C. Revisions in the International System for Staging Lung Cancer. Chest. 1997;111:1710–1717
  3. Proceedings of the European Consensus Conference on Medical Treatment of Non-small Lung Cancer. Lung Cancer 2002;38(suppl 3):S1–85.
  4. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized trials. BMJ. 1995;311:899–909
  5. Simon GR, Wagner H. Small cell lung cancer. Chest. 2003;123:259S–271S
  6. Silvestri G, Pritchard R, Welch HG. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ. 1998;317:771–775
  7. Berkun Y, Levartovsky D, Rubinow A, Orbach H, Aamar S, Grenader T, et al. Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene. Ann Rheum Dis. 2004;63:1227–1231
  8. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004;22:1382–1388
  9. Yonemori K, Ueno H, Okusaka T, Yamamoto N, Ikeda M, Saijo N, et al. Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin Cancer Res. 2005;11:2620–2624
  10. Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, Stangeland L, et al. Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis. 2006;27:560–567
  11. Xing D, Qi J, Miao X, Lu W, Tan W, Lin D. Polymorphisms of DNA repair genes XRCC1 and XPD and their associations with risk of esophageal squamous cell carcinoma in a Chinese population. Int J Cancer. 2002;100:600–605
  12. Park JY, Lee SY, Jeon HS, Bae NC, Chae SC, Joo S, et al. Polymorphism of the DNA repair gene XRCC1 and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev. 2002;11:23–27
  13. Hung RJ, Brennan P, Canzian F, Szeszenia-Dabrowska N, Zaridze D, Lissowska J, et al. Large-scale investigation of base excision repair genetic polymorphisms and lung cancer risk in a multicenter study. J Natl Cancer Inst. 2005;97:567–576
  14. Isla D, Sarries C, Rosell R, Alonso G, Alonso G, Domine M, et al. Single nucleotide polymorphisms and outcome in docetaxel–cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol. 2004;15:1194–1203
  15. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res. 2001;61:8654–8658
  16. de las Peñas R, Sanchez-Ronco M, Alberola V, Taron M, Camps C, Garcia-Carbonero R, et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol. 2006;17:668–675
  17. Wei Q, Frazier ML, Levin B. DNA repair: a double-edged sword. J Natl Cancer Inst. 2000;92:440–441
  18. Rosell R, Lord RV, Taron M, Reguart N. DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer. 2002;38:217–227
  19. Lunn RM, Langlois RG, Hsieh LL, Thompson CL, Bell DA. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res. 1999;59:2557–2561
  20. El-Khamisy SF, Masutani M, Suzuki H, Caldecott KW. A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Res. 2003;31:5526–5533
  21. Chen S, Tang D, Xue K, Xu L, Ma G, Hsu Y, et al. DNA repair gene XRCC1 and XPD polymorphisms and risk of lung cancer in a Chinese population. Carcinogenesis. 2002;23:1321–1325
  22. Zhang X, Miao X, Liang G, Hao B, Wang Y, Tan W, et al. Polymorphisms in DNA base excision repair genes ADPRT and XRCC1 and risk of lung cancer. Cancer Res. 2005;65:722–726
  23. Rybicki BA, Conti DV, Moreira A, Cicek M, Casey G, Witte JS. DNA repair gene XRCC1 and XPD polymorphisms and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2004;13:23–29
  24. Duell EJ, Millikan RC, Pittman GS, Winkel S, Lunn RM, Tse CK, et al. Polymorphisms in the DNA repair gene XRCC1 and breast cancer. Cancer Epidemiol Biomarkers Prev. 2001;10:217–222
  25. Cho EY, Hildesheim A, Chen CJ, Hsu MM, Chen IH, Mittl BF, et al. Nasopharyngeal carcinoma and genetic polymorphisms of DNA repair enzymes XRCC1 and hOGG1. Cancer Epidemiol Biomarkers Prev. 2003;12:1100–1104
  26. Lee SG, Kim B, Choi J, Kim C, Lee I, Song K. Genetic polymorphisms of XRCC1 and risk of gastric cancer. Cancer Lett. 2002;187:53–60
  27. Patel AV, Calle EE, Pavluck AL, Feigelson HS, Thun MJ, Rodriguez C. A prospective study of XRCC1 (X-ray cross-complementing group 1) polymorphisms and breast cancer risk. Breast Cancer Res. 2005;7:R1168–R1173
  28. Wang ZH, Miao XP, Tan W, Zhang XR, Xu BH, Lin DX. Single nucleotide polymorphisms in XRCC1 and clinical response to platin-based chemotherapy in advanced non-small cell lung cancer. Ai Zheng. 2004;23:865–868[Article in Chinese]
  29. Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol. 2004;22:2594–2601
  30. Stoehlmacher J, Ghaderi V, Iobal S, Groshen S, Tsao-Wei D, Park D, et al. A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res. 2001;21:3075–3079
  31. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 2000;60:6921–6926

PII: S0169-5002(08)00107-4

doi: 10.1016/j.lungcan.2008.02.019

Lung Cancer
Volume 62, Issue 1 , Pages 99-104 , October 2008

Article Tools